The Enhanced Liver Fibrosis (ELF) Test from Siemens Healthineers is now available in the United States, providing broad clinical access to the minimally invasive prognostic tool. Currently, the ELF ...
Disclaimer: The products/features (mentioned herein) are not commercially available in all countries. Their future availability cannot be guaranteed. In the U.S., the ELF Test is indicated as a ...
Background: FibroTest (FT) is the most frequently used serum fibrosis marker and consists of an algorithm of five fibrosis markers (alfa2-macroglobulin, apolipoproteinA1, haptoglobin, GGT, bilirubin).
The Enhanced Liver Fibrosis (ELF) is the first prognostic tool for patients with advanced fibrosis (F3 or F4) due to non-alcoholic steatohepatitis (NASH) to be granted De Novo marketing authorization.
Siemens is launching a new diagnostic amid a rise in liver damage cases caused by so-called fatty-liver disease. (Database Center for Life Science/CC BY-SA 2.1) () Siemens is launching its Enhanced ...
At present, transient elastography and the serum marker FibroTest are the most intensively evaluated non-invasive methods for the assessment of liver fibrosis. The results of the present study for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results